Ashley Gallagher, Editor

The biosimilar matches Prolia in efficacy, immunogenicity, pharmacodynamics, and pharmacokinetics in women who are postmenopausal with osteoporosis.

Janssen’s GUIDE data demonstrate that patients treated with guselkumab less than 2 years after disease onset vs later are more likely to achieve “super-responder” at week 20 through 28.

Pivotal top-line data demonstrate 20vPnC, if approved likely protects against 20 serotypes in 3-dose series and may offer the broadest serotype coverage of any PCV.

Phase 3 TOPAZ-1 trial of AstraZeneca’s durvalumab demonstrates an improved overall survival benefit.

AstraZeneca’s Lynparza in combination or as a monotherapy demonstrates meaningful survival benefit in long-term follow-up.

Receiving benefits from the SNAP program does not alleviate the issue, according to the analysis.

Analysis shows that individuals who are comfortable sharing their identities with providers are more likely to be satisfied with overall care.

USC Analysis: although generics save US health care systems billions, PBMs jack up prices for employers, government, and patients.

DaxibotulinumtoxinA-lanm from Revance Therapeutics Inc is the first peptide-formulated neuromodulator with long-lasting results.

Panelists discuss pharmacist involvement in effective management, including disease burden and quality of life.

Triplet combination demonstrates a reduction in the risk of disease progression or death in individuals with previously untreated advanced intermediate- or poor-risk renal cell carcinoma.

Part A results from the 2-part LILAC study show that the therapy significantly reduced disease activity based on active joint count in individuals compared with the placebo.

The long-acting, once-daily hormone controls high blood sugar in individuals aged 1 year or older with diabetes.

Therapy shows positive clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients who have a KRASG12C mutation.

Investigators find 8 of 10 of the most common symptoms were reported between 50% and 80% less often among those who received at least 2 Pfizer-BioNTech vaccinations.

Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.

An estimated 31.4% of individuals with non-squamous non–small cell lung cancer treated with the combination were alive at 3 years compared to 17.3% for those on chemotherapy alone.

Boehringer Ingelheim’s monoclonal antibody inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for this indication.

Modification is based on phase 3 FIGARO-DKD clinical trial investigating CV and kidney outcomes in more than 13,000 patients with CKD associated with type 2 diabetes.

Decision is based on interim analysis of Pfizer’s GBS6 in healthy pregnant woman aged 18 to 40 years, who were vaccinated during their second or early third trimesters.

Analysis presented at an American Heart Association meeting suggests that following DASH is most effective to reduce the risk of heart attacks and strokes.

But the 2021 modifications to the US Preventive Services Task Force recommendations do not eliminate the inequalities, analysis shows.

The findings also indicate that that treatment may have protective CV and limb benefits for those with kidney failure and concomitant peripheral artery disease.

Because there is no vaccine for the disease, preventive strategies are needed, investigators from Copenhagen University Hospital in Denmark say.

New TROPiCS-02 data for Gilead treatment demonstrates progression-free survival benefit, regardless of HER2 status.

Patients should discuss efficacy and potential drug interactions with clinicians before use, study authors indicate.

University of California Irvine investigators spotlight links and propose further systematic examination into the molecular underpinnings.

Findings have implications for patients who take supplementary folate to prevent complications of other pharmacological therapies.

The agency’s decision data for the investigational factor VIII therapy from Sanofi and Soba is set for February 28, 2023.

One-third of participants who have used prescriptions think that mail-order pharmacies would help reduce drug costs, according to HealthCare.com.